Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn).
Guerra
E
E
Department of Allergy and Clinical Immunology, University of Rome La Sapienza, Italy.
Ricci
G
G
Carlesimo
M
M
Varani
A R
AR
Pontesilli
O
O
Scala
E
E
Mezzaroma
I
I
Pierdominici
Pandolfi
F
F
Antinori
A
A
De Luca
A
A
Murri
R
R
Ammassari
A
A
Ortona
L
L
Aiuti
F
F
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active; D008297:Male; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology; D015215:Zidovudine / Q000008:administration & dosage
D016915:AIDS Vaccines; D000998:Antiviral Agents; D014614:Vaccines, Synthetic; C053473:VaxSyn HIV-1 (gp160) vaccine; D015215:Zidovudine